ABSTRACT
There is a need to treat COVID-19 patients suffering from respiratory problems, resulting in decreased oxygen levels and thus leading to mitochondrial dysfunction and metabolic abnormalities. Here, we investigated if a high oral dose of a mixture of Combined Metabolic Activators (CMA) can restore metabolic function and thus aid the recovery of COVID-19 patients. We conducted a placebo-controlled, open-label phase 2 study and a double-blinded phase 3 clinical trials to investigate the time of symptom-free recovery on ambulatory patients using a mixture of CMA consisting of NAD+ and glutathione precursors. The results of both studies showed that the time to complete recovery was significantly shorter in the CMA group (6.6 vs 9.3 days) in phase 2 and (5.7 vs 9.2 days) in phase 3 trials. A comprehensive analysis of the blood metabolome and proteome showed that the plasma levels of proteins and metabolites associated with inflammation and antioxidant metabolism are significantly improved in patients treated with the metabolic activators as compared to placebo. The results show that treating patients infected with COVID-19 with a high dose of CMAs leads to a more rapid symptom-free recovery, suggesting a role for such a therapeutic regime in the treatment of infections leading to respiratory problems.
- COVID-19
- Combined Metabolic Activators
- proteomics
- metabolomics
- omics data
Competing Interest Statement
AM, JB and MU filed a patent application on the use of CMA on COVID-19 patients. The other authors declare no competing interests.
Clinical Trial
ClinicalTrials.gov NCT04573153
Funding Statement
This work was supported by Knut and Alice Wallenberg Foundation. The authors would like to thank ChromaDex (Irvine, CA, USA) for providing NR for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the ethics committee of Istanbul Medipol University. Decision No:45 Decision Date: 28/05/2020 Members of Ethics Committee: Professor Hanefi OZBEK Professor Gurkan OZTURK Professor Fulya IlCin GONENC Professor Abdulbari BENER Associate Professor Ali OZTURK Associate Professor Bahri TEKER Associate Professor Muhammed Fatih EVCIMIK
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Emails: havva.altay{at}scilifelab.se; muhammad.arif{at}scilifelab.se; xiangyu.li{at}scilifelab.se; hong.yang{at}scilifelab.se; mehtapaydin10{at}gmail.com; alkurt.gizem{at}gmail.com; woonghee.kim{at}scilifelab.se; akyol_dogukan{at}hotmail.com; cheng.zhang{at}scilifelab.se; gddoganay{at}itu.edu.tr; hturkez{at}atauni.edu.tr; saeed.shoaie{at}kcl.ac.uk; nielsenj{at}chalmers.se; jan.boren{at}wlab.gu.se; oolmuscelik{at}medipol.edu.tr; levent.doganay{at}saglik.gov.tr; mathias.uhlen{at}scilifelab.se; adilm{at}scilifelab.se
Data Availability
The data that support the findings of this study are available from the corresponding author [adilm@scilifelab.se], upon reasonable request.
